ES2647917T3 - Neuregulina para uso en el tratamiento de una lesión de nervio periférico - Google Patents
Neuregulina para uso en el tratamiento de una lesión de nervio periférico Download PDFInfo
- Publication number
- ES2647917T3 ES2647917T3 ES13716919.9T ES13716919T ES2647917T3 ES 2647917 T3 ES2647917 T3 ES 2647917T3 ES 13716919 T ES13716919 T ES 13716919T ES 2647917 T3 ES2647917 T3 ES 2647917T3
- Authority
- ES
- Spain
- Prior art keywords
- injury
- weeks
- nerve
- animals
- ggf2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000014413 Neuregulin Human genes 0.000 title abstract description 19
- 108050003475 Neuregulin Proteins 0.000 title abstract description 19
- 208000010886 Peripheral nerve injury Diseases 0.000 title abstract description 14
- 238000011282 treatment Methods 0.000 title description 18
- 238000000034 method Methods 0.000 abstract description 14
- 239000000203 mixture Substances 0.000 abstract description 11
- 238000001356 surgical procedure Methods 0.000 abstract description 11
- 208000004296 neuralgia Diseases 0.000 abstract description 5
- 208000021722 neuropathic pain Diseases 0.000 abstract description 5
- 230000006378 damage Effects 0.000 description 38
- 208000014674 injury Diseases 0.000 description 35
- 208000027418 Wounds and injury Diseases 0.000 description 34
- 241001465754 Metazoa Species 0.000 description 31
- 210000005036 nerve Anatomy 0.000 description 16
- 238000004088 simulation Methods 0.000 description 12
- 210000003050 axon Anatomy 0.000 description 11
- 208000025962 Crush injury Diseases 0.000 description 10
- 208000028389 Nerve injury Diseases 0.000 description 10
- 230000008764 nerve damage Effects 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 7
- 210000000578 peripheral nerve Anatomy 0.000 description 7
- 230000008929 regeneration Effects 0.000 description 7
- 238000011069 regeneration method Methods 0.000 description 7
- 208000004454 Hyperalgesia Diseases 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 210000004116 schwann cell Anatomy 0.000 description 6
- 210000003497 sciatic nerve Anatomy 0.000 description 6
- 206010016654 Fibrosis Diseases 0.000 description 5
- 230000004761 fibrosis Effects 0.000 description 5
- 201000001881 impotence Diseases 0.000 description 5
- 210000001087 myotubule Anatomy 0.000 description 5
- 230000001953 sensory effect Effects 0.000 description 5
- 208000010228 Erectile Dysfunction Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000007906 compression Methods 0.000 description 4
- 230000006835 compression Effects 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000037152 sensory function Effects 0.000 description 4
- 230000000472 traumatic effect Effects 0.000 description 4
- 208000000094 Chronic Pain Diseases 0.000 description 3
- 208000035154 Hyperesthesia Diseases 0.000 description 3
- 206010053552 allodynia Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241001091538 Dimorphandra Group A Species 0.000 description 2
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010048654 Muscle fibrosis Diseases 0.000 description 2
- 108010083674 Myelin Proteins Proteins 0.000 description 2
- 102000006386 Myelin Proteins Human genes 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 101000653754 Rattus norvegicus Sphingosine 1-phosphate receptor 5 Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 210000003766 afferent neuron Anatomy 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 230000009986 erectile function Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000007659 motor function Effects 0.000 description 2
- 210000005012 myelin Anatomy 0.000 description 2
- 230000003040 nociceptive effect Effects 0.000 description 2
- 230000008058 pain sensation Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000008447 perception Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000020341 sensory perception of pain Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 210000003594 spinal ganglia Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 150000004992 toluidines Chemical class 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 101100316741 Danio rerio slc18a3b gene Proteins 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 101000979249 Homo sapiens Neuromodulin Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 102100023206 Neuromodulin Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 241000906034 Orthops Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010061336 Pelvic neoplasm Diseases 0.000 description 1
- 206010067633 Peripheral nerve lesion Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010039670 Sciatic nerve injury Diseases 0.000 description 1
- 101150088805 Slc18a3 gene Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 206010073696 Wallerian degeneration Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000032459 dedifferentiation Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003562 morphometric effect Effects 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- 230000023105 myelination Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007372 neural signaling Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000003227 neuromodulating effect Effects 0.000 description 1
- 230000007991 neuronal integrity Effects 0.000 description 1
- 230000009689 neuronal regeneration Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000018052 penile erection Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000011471 prostatectomy Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011472 radical prostatectomy Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000008734 wallerian degeneration Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261618381P | 2012-03-30 | 2012-03-30 | |
| US201261618381P | 2012-03-30 | ||
| US201261674060P | 2012-07-20 | 2012-07-20 | |
| US201261674060P | 2012-07-20 | ||
| US201261693585P | 2012-08-27 | 2012-08-27 | |
| US201261693589P | 2012-08-27 | 2012-08-27 | |
| US201261693589P | 2012-08-27 | ||
| US201261693585P | 2012-08-27 | ||
| US201361785419P | 2013-03-14 | 2013-03-14 | |
| US201361785419P | 2013-03-14 | ||
| PCT/US2013/034634 WO2013149163A1 (en) | 2012-03-30 | 2013-03-29 | Use of neuregulin to treat peripheral nerve injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2647917T3 true ES2647917T3 (es) | 2017-12-27 |
Family
ID=48128617
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13716919.9T Active ES2647917T3 (es) | 2012-03-30 | 2013-03-29 | Neuregulina para uso en el tratamiento de una lesión de nervio periférico |
| ES17187879T Active ES2857810T3 (es) | 2012-03-30 | 2013-03-29 | Uso de GGF2 para tratar el dolor neuropático luego de lesión del nervio periférico |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17187879T Active ES2857810T3 (es) | 2012-03-30 | 2013-03-29 | Uso de GGF2 para tratar el dolor neuropático luego de lesión del nervio periférico |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20150094263A1 (enExample) |
| EP (3) | EP2830645B1 (enExample) |
| JP (4) | JP6420233B2 (enExample) |
| CN (2) | CN104321072A (enExample) |
| AU (4) | AU2013237896B2 (enExample) |
| BR (1) | BR112014024308B1 (enExample) |
| CA (1) | CA2869070A1 (enExample) |
| DK (2) | DK3278811T3 (enExample) |
| ES (2) | ES2647917T3 (enExample) |
| IL (3) | IL288785B2 (enExample) |
| MX (1) | MX354598B (enExample) |
| NZ (1) | NZ700546A (enExample) |
| PL (2) | PL3278811T3 (enExample) |
| PT (2) | PT2830645T (enExample) |
| WO (1) | WO2013149163A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3338791T3 (da) | 2008-07-17 | 2019-12-16 | Acorda Therapeutics Inc | Terapeutisk dosering af en neuregulin i behandling eller profylaxis af hjertesvigt |
| PL3235504T3 (pl) | 2009-10-14 | 2020-03-31 | Acorda Therapeutics, Inc. | Zastosowanie neureguliny do leczenia uszkodzenia nerwu obwodowego |
| ITUB20155471A1 (it) * | 2015-11-11 | 2017-05-11 | Univ Degli Studi Di Torino | Coniugato della neuregulina 1 per il trattamento delle lesioni dei nervi periferici |
| IL294038A (en) * | 2015-12-04 | 2022-08-01 | Univ Iowa Res Found | Device, systems and methods for prediction, screening and monitoring of encephalopathy / delirium |
| CA3082878C (en) | 2017-11-17 | 2024-02-20 | The Research Foundation for State University of New York | A method for treating damaged peripheral nerves using x-ray microbeam irradiation |
| CN110946991A (zh) * | 2018-09-27 | 2020-04-03 | 广州中医药大学(广州中医药研究院) | 神经调节蛋白1的应用 |
| CN114929099B (zh) * | 2019-08-01 | 2025-08-15 | 马克·埃文斯 | 用于在分娩期间和分娩之前降低人类胎儿神经损伤风险及鉴定神经损伤存在的方法和设备 |
| CN116116737B (zh) * | 2023-04-14 | 2023-06-30 | 新华手术器械有限公司 | 止血钳毛坯自动上料装置及使用方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US888A (en) | 1838-08-20 | perkins | ||
| US7037A (en) | 1850-01-22 | Grid-ikon slide-valve | ||
| US5716930A (en) | 1991-04-10 | 1998-02-10 | Ludwig Institute For Cancer Research | Glial growth factors |
| US5530109A (en) | 1991-04-10 | 1996-06-25 | Ludwig Institute For Cancer Research | DNA encoding glial mitogenic factors |
| US6087323A (en) * | 1992-04-03 | 2000-07-11 | Cambridge Neuroscience, Inc. | Use of neuregulins as modulators of cellular communication |
| US7037888B1 (en) | 1992-04-03 | 2006-05-02 | Acorda Therapeutics, Inc. | Methods for treating muscle diseases and disorders |
| EP1028735A4 (en) * | 1997-10-14 | 2003-08-06 | Cenes Pharmaceuticals Inc | THERAPEUTIC METHOD COMPRISING THE USE OF NEUREGULIN |
| CA2409996C (en) * | 2000-05-23 | 2016-03-01 | Cenes Pharmaceuticals, Inc. | Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| WO2009046453A2 (en) * | 2007-10-05 | 2009-04-09 | New England Medical Center (Nemc) | Use of neuregulin-1 in reducing brain damage |
| CN104645315A (zh) * | 2008-02-29 | 2015-05-27 | 阿索尔达治疗公司 | 达到所需胶质生长因子2血浆水平的方法 |
| DK3338791T3 (da) * | 2008-07-17 | 2019-12-16 | Acorda Therapeutics Inc | Terapeutisk dosering af en neuregulin i behandling eller profylaxis af hjertesvigt |
| KR101237927B1 (ko) * | 2009-05-07 | 2013-03-04 | (주)문엔제이 | 신경손상 및 신경질환 예방 또는 치료용 약학조성물 |
| PL3235504T3 (pl) * | 2009-10-14 | 2020-03-31 | Acorda Therapeutics, Inc. | Zastosowanie neureguliny do leczenia uszkodzenia nerwu obwodowego |
| CA2845198A1 (en) * | 2010-08-13 | 2012-02-16 | Georgetown University | Ggf2 and methods of use |
-
2013
- 2013-03-29 DK DK17187879.6T patent/DK3278811T3/da active
- 2013-03-29 AU AU2013237896A patent/AU2013237896B2/en not_active Ceased
- 2013-03-29 EP EP13716919.9A patent/EP2830645B1/en active Active
- 2013-03-29 JP JP2015503646A patent/JP6420233B2/ja not_active Expired - Fee Related
- 2013-03-29 IL IL288785A patent/IL288785B2/en unknown
- 2013-03-29 PL PL17187879T patent/PL3278811T3/pl unknown
- 2013-03-29 US US14/389,655 patent/US20150094263A1/en not_active Abandoned
- 2013-03-29 ES ES13716919.9T patent/ES2647917T3/es active Active
- 2013-03-29 CN CN201380026579.2A patent/CN104321072A/zh active Pending
- 2013-03-29 CN CN201610027758.3A patent/CN106511971A/zh active Pending
- 2013-03-29 PT PT137169199T patent/PT2830645T/pt unknown
- 2013-03-29 PT PT171878796T patent/PT3278811T/pt unknown
- 2013-03-29 CA CA2869070A patent/CA2869070A1/en active Pending
- 2013-03-29 PL PL13716919T patent/PL2830645T3/pl unknown
- 2013-03-29 WO PCT/US2013/034634 patent/WO2013149163A1/en not_active Ceased
- 2013-03-29 EP EP17187879.6A patent/EP3278811B1/en active Active
- 2013-03-29 ES ES17187879T patent/ES2857810T3/es active Active
- 2013-03-29 NZ NZ700546A patent/NZ700546A/en not_active IP Right Cessation
- 2013-03-29 BR BR112014024308-5A patent/BR112014024308B1/pt not_active IP Right Cessation
- 2013-03-29 DK DK13716919.9T patent/DK2830645T3/da active
- 2013-03-29 EP EP20211026.8A patent/EP3842059A1/en not_active Withdrawn
- 2013-03-29 MX MX2014011838A patent/MX354598B/es active IP Right Grant
-
2014
- 2014-09-29 IL IL234882A patent/IL234882B/en active IP Right Grant
-
2015
- 2015-12-22 US US14/978,287 patent/US20160346353A1/en not_active Abandoned
-
2017
- 2017-04-07 JP JP2017076415A patent/JP2017149746A/ja active Pending
-
2018
- 2018-01-24 AU AU2018200592A patent/AU2018200592A1/en not_active Abandoned
-
2019
- 2019-04-03 JP JP2019070976A patent/JP2019131582A/ja active Pending
- 2019-04-05 AU AU2019202401A patent/AU2019202401B2/en not_active Ceased
-
2020
- 2020-03-09 IL IL273186A patent/IL273186B/en unknown
- 2020-10-30 AU AU2020260539A patent/AU2020260539A1/en not_active Abandoned
-
2021
- 2021-01-15 JP JP2021004728A patent/JP7108724B2/ja active Active
-
2022
- 2022-03-28 US US17/705,840 patent/US20230117985A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2647917T3 (es) | Neuregulina para uso en el tratamiento de una lesión de nervio periférico | |
| US20220306704A1 (en) | Neurotoxins for use in inhibiting cgrp | |
| Soleman et al. | Targeting the neural extracellular matrix in neurological disorders | |
| Srinivas et al. | Efficacy of riluzole in the treatment of spinal cord injury: a systematic review of the literature | |
| ES2374712T3 (es) | Proteína antisecretora para uso en el tratamiento del síndrome compartimental. | |
| ES2439740T3 (es) | Tratamientos para trastornos neurológicos | |
| KR20050109969A (ko) | 보툴리눔 톡신으로 부비동염 관련 만성 안면통 및 두통을치료하는 방법 | |
| Yin et al. | Transcorneal electrical stimulation promotes survival of retinal ganglion cells after optic nerve transection in rats accompanied by reduced microglial activation and TNF-α expression | |
| Smith et al. | Effects of nicotinamide on spatial memory and inflammation after juvenile traumatic brain injury | |
| Welin et al. | Effects of N-acetyl-cysteine on the survival and regeneration of sural sensory neurons in adult rats | |
| Uzun et al. | Evaluation and comparison of the effects of artesunate, dexamethasone, and tacrolimus on sciatic nerve regeneration | |
| Hajimashhadi et al. | Chronic administration of [Pyr1] apelin-13 attenuates neuropathic pain after compression spinal cord injury in rats | |
| ES2880807T3 (es) | Administración intranasal de agentes con actividad pro-inflamatoria para la terapia de trastornos neurológicos | |
| Johnson et al. | Combined regenerative rehabilitation improves recovery following volumetric muscle loss injury in a rat model | |
| US20250134946A1 (en) | Self-assembling amphiphilic peptide hydrogels for treatment of nerve injury | |
| ES2763086T3 (es) | Uso de una neuregulina para tratar la lesión del nervio periférico | |
| ES2930077T3 (es) | Apelina para su uso en el tratamiento de la disfunción cognitiva posoperatoria | |
| Feng et al. | Clinical therapeutic guideline for neurorestoration in spinal cord injury (Chinese version 2016) | |
| KR20190142404A (ko) | 보툴리눔 독소 및 히알루론산을 포함하는 족부통증 질환 치료용 약학적 조성물 및 이를 이용한 족부통증 질환 치료방법 | |
| ES2771448T3 (es) | La protamina en el tratamiento de las lesiones neuronales | |
| Ara et al. | Effect of various treatment modalities after spinal cord injury | |
| Archer et al. | The skin and the nervous system | |
| Akshaya et al. | Effect of Dry Needling on Patients with Lumbar Radiculopathy in Reducing Pain and Increasing Range of Motion Compared to Interferential Therapy. | |
| Sohn et al. | Microelectric Treatment by Transcutaneous Electrical Nerve Stimulation in a Rat Model of Acute Spinal Cord Injury | |
| RU2201266C2 (ru) | Способ лечения болевых и компрессионных синдромов поясничного остеохондроза |